Noxopharm Ltd V.NOX

Primary Symbol: NOXOF

Healthcare Biotechnology

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.

OTCPK:NOXOF - Post by User

Noxopharm Ltd

Bullboard Posts

Post by jsnfernleyon Jan 28, 2010 9:47am

473 Views

Post# 16727518

No--959k oz Au

Add up all of the bold/highlighted Indicated and Inferred figures for Norlartic-Kierens and Marban and you come up with 959k oz. The other figures are for looking at the resources with different cut-off grades.Plus, you still have the historical non 43-101 compliant resources from the other zones of 170k Au.

Bullboard Posts

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide